As of May 27, 2025, Amryt Pharma Holdings Ltd has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $143.00, this represents a potential upside of -21048.8%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -2394.0% |
| Potential Upside (10-year) | -21048.8% |
| Discount Rate (WACC) | 7.2% - 9.3% |
Revenue is projected to grow from $183 million in 12-2020 to $21607 million by 12-2030, representing a compound annual growth rate of approximately 61.1%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2020 | 183 | 214% |
| 12-2021 | 213 | 17% |
| 12-2022 | 316 | 49% |
| 12-2023 | 407 | 29% |
| 12-2024 | 831 | 104% |
| 12-2025 | 1621 | 95% |
| 12-2026 | 2957 | 82% |
| 12-2027 | 5199 | 76% |
| 12-2028 | 8785 | 69% |
| 12-2029 | 14052 | 60% |
| 12-2030 | 21607 | 54% |
Net profit margin is expected to improve from -57% in 12-2020 to -41% by 12-2030, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2020 | (105) | -57% |
| 12-2021 | (116) | -55% |
| 12-2022 | (163) | -52% |
| 12-2023 | (198) | -49% |
| 12-2024 | (381) | -46% |
| 12-2025 | (700) | -43% |
| 12-2026 | (1,262) | -43% |
| 12-2027 | (2,192) | -42% |
| 12-2028 | (3,660) | -42% |
| 12-2029 | (5,787) | -41% |
| 12-2030 | (8,793) | -41% |
with a 5-year average of $1 million. Projected CapEx is expected to maintain at approximately 1% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2021 | 1 |
| 12-2022 | 2 |
| 12-2023 | 3 |
| 12-2024 | 6 |
| 12-2025 | 10 |
| 12-2026 | 18 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 145 |
| Days Inventory | 266 |
| Days Payables | 104 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 3M/2021 | (23) | (0) | 1 | 15 | (39) |
| 2022 | (127) | (0) | 5 | 130 | (262) |
| 2023 | (151) | (0) | 6 | (13) | (144) |
| 2024 | (286) | (1) | 12 | 315 | (613) |
| 2025 | (517) | (1) | 24 | 553 | (1,092) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -2394.0% |
| 10-Year DCF (Growth) | 0.00 | -21048.8% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Amryt Pharma Holdings Ltd (AMYT.L) a buy or a sell? Amryt Pharma Holdings Ltd is definitely a sell. Based on our DCF analysis, Amryt Pharma Holdings Ltd (AMYT.L) appears to be overvalued with upside potential of -21048.8%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $143.00.